secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001558370-24-004527
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences reports FY2023 net loss $13.2M, cash $12.6M; PMN310 Phase 1a data on track for mid-2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $12.6M at Dec 31, 2023, up from $5.9M; Q3 2023 PIPE raised $20.4M gross.
- Net loss $13.2M for FY2023 vs $18.1M in FY2022; R&D expenses $7.9M vs $16.1M.
- Phase 1a trial of PMN310 for Alzheimer's dosed Nov 2023; top-line safety/PK data expected mid-2024.
- Lead vaccine candidate PMN400 selected for synucleinopathies (MSA, Parkinson's) in Jan 2024.
- Neil Warma appointed interim CEO in Jan 2024; US/international patent allowances for AD antibody in Mar 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/0001558370-24-004527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/pmn-20240401x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer